193 related articles for article (PubMed ID: 38010250)
1. [New Therapeutic Strategies in the Treatment of CKD Anemia: Hypoxia-Induced Factor Prolyl-Hydroxylase Inhibitors].
Taurisano M; Protopapa P; Barbarini S; Mancini A; Cortese C; Napoli M
G Ital Nefrol; 2023 Oct; 40(5):. PubMed ID: 38010250
[TBL] [Abstract][Full Text] [Related]
2. A network meta-analysis of the efficacy of hypoxia-inducible factor prolyl-hydroxylase inhibitors in dialysis chronic kidney disease.
Chen J; Shou X; Xu Y; Jin L; Zhu C; Ye X; Mei Z; Chen P
Aging (Albany NY); 2023 Mar; 15(6):2237-2274. PubMed ID: 36988549
[TBL] [Abstract][Full Text] [Related]
3. Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors
Yang J; Xing J; Zhu X; Xie X; Wang L; Zhang X
Front Endocrinol (Lausanne); 2023; 14():1131516. PubMed ID: 37008953
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: A meta-analysis including 13,146 patients.
Chen H; Cheng Q; Wang J; Zhao X; Zhu S
J Clin Pharm Ther; 2021 Aug; 46(4):999-1009. PubMed ID: 33615523
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis.
Zheng Q; Yang H; Sun L; Wei R; Fu X; Wang Y; Huang Y; Liu YN; Liu WJ
Pharmacol Res; 2020 Sep; 159():105020. PubMed ID: 32561478
[TBL] [Abstract][Full Text] [Related]
6. Effect of hypoxia-inducible factor-prolyl hydroxylase inhibitors on anemia in patients with CKD: a meta-analysis of randomized controlled trials including 2804 patients.
Wang B; Yin Q; Han YC; Wu M; Li ZL; Tu Y; Zhou LT; Wei Q; Liu H; Tang RN; Cao JY; Lv LL; Liu BC
Ren Fail; 2020 Nov; 42(1):912-925. PubMed ID: 32869703
[TBL] [Abstract][Full Text] [Related]
7. Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors.
Sugahara M; Tanaka T; Nangaku M
Pharmacol Ther; 2022 Nov; 239():108272. PubMed ID: 36031160
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience.
Sanghani NS; Haase VH
Adv Chronic Kidney Dis; 2019 Jul; 26(4):253-266. PubMed ID: 31477256
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages.
Mima A
Eur J Pharmacol; 2021 Dec; 912():174583. PubMed ID: 34678238
[TBL] [Abstract][Full Text] [Related]
10. Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF-Prolyl Hydroxylase Inhibitors.
Locatelli F; Minutolo R; De Nicola L; Del Vecchio L
Drugs; 2022 Nov; 82(16):1565-1589. PubMed ID: 36350500
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia-Inducible Factor Stabilization as an Emerging Therapy for CKD-Related Anemia: Report From a Scientific Workshop Sponsored by the National Kidney Foundation.
Wish JB; Eckardt KU; Kovesdy CP; Fishbane S; Spinowitz BS; Berns JS
Am J Kidney Dis; 2021 Nov; 78(5):709-718. PubMed ID: 34332007
[TBL] [Abstract][Full Text] [Related]
12. New developments in anaemia treatment - erythropoietin versus prolyl hydroxylase inhibitors?
Ryšavá R
Vnitr Lek; 2022; 68(7):438-443. PubMed ID: 36402568
[TBL] [Abstract][Full Text] [Related]
13. Roxadustat in the treatment of anaemia in chronic kidney disease.
Del Vecchio L; Locatelli F
Expert Opin Investig Drugs; 2018 Jan; 27(1):125-133. PubMed ID: 29254377
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease?
Souza E; Cho KH; Harris ST; Flindt NR; Watt RK; Pai AB
Expert Opin Investig Drugs; 2020 Aug; 29(8):831-844. PubMed ID: 32476498
[TBL] [Abstract][Full Text] [Related]
15. Treatment of anemia associated with chronic kidney disease with the HIF prolyl hydroxylase inhibitor enarodustat: A review of the evidence.
Fujikawa R; Nagao Y; Fujioka M; Akizawa T
Ther Apher Dial; 2022 Aug; 26(4):679-693. PubMed ID: 35218616
[TBL] [Abstract][Full Text] [Related]
16. Iron Regulation by Molidustat, a Daily Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, in Patients with Chronic Kidney Disease.
Akizawa T; Macdougall IC; Berns JS; Yamamoto H; Taguchi M; Iekushi K; Bernhardt T
Nephron; 2019; 143(4):243-254. PubMed ID: 31387097
[TBL] [Abstract][Full Text] [Related]
17. Are there advantages of daprodustat over erythropoiesis-stimulating agents (ESAs) in treating anemia associated with chronic kidney disease (CKD)?
Doggrell SA
Expert Opin Pharmacother; 2022 May; 23(7):769-773. PubMed ID: 35380500
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD.
Gupta N; Wish JB
Am J Kidney Dis; 2017 Jun; 69(6):815-826. PubMed ID: 28242135
[TBL] [Abstract][Full Text] [Related]
19. Comparison of outcomes on hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) in anaemia associated with chronic kidney disease: network meta-analyses in dialysis and non-dialysis dependent populations.
Sackeyfio A; Lopes RD; Kovesdy CP; Cases A; Mallett SA; Ballew N; Keeley TJ; Garcia-Horton V; Ayyagari R; Camejo RR; Johansen KL; Sutton AJ; Dasgupta I
Clin Kidney J; 2024 Jan; 17(1):sfad298. PubMed ID: 38250252
[TBL] [Abstract][Full Text] [Related]
20. Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease.
Del Vecchio L; Locatelli F
Expert Opin Investig Drugs; 2018 Jul; 27(7):613-621. PubMed ID: 29975110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]